Unknown

Dataset Information

0

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.

ABSTRACT:

SUBMITTER: Socinski MA 

PROVIDER: S-EPMC8140815 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.

Socinski Mark A MA   Pennell Nathan A NA   Davies Kurtis D KD  

JCO precision oncology 20210413

Similar Datasets

Unknown [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
| S-EPMC6058657 | biostudies-literature
Unknown MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
| S-EPMC4828128 | biostudies-literature
Unknown Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.
| S-EPMC8422679 | biostudies-literature
Unknown MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
| S-EPMC7729352 | biostudies-literature
Unknown MET targeted therapy in non-small cell lung cancer patients with <i>MET</i> exon 14-skipping mutations.
| S-EPMC11082700 | biostudies-literature
Unknown A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations.
| S-EPMC8044480 | biostudies-literature
Unknown MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
| S-EPMC6675391 | biostudies-literature
Unknown MET Exon 14 Skipping Mutations in Lung Cancer: Clinical-Pathological Characteristics and Immune Microenvironment.
| S-EPMC12293242 | biostudies-literature
Unknown MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
| S-EPMC4911276 | biostudies-literature
Unknown Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
| S-EPMC4658654 | biostudies-literature